Ann: Quarterly Activities/Appendix 4C Cash Flow Report, page-30

LDX had purchased around 100,000 pascal units from AT1 over the previous 6 months to December last year.

Units being sold now, could include those units purchased in previous quarters and further spend on uptake over the coming months and into the new year.

The thing I see as a positive is the seasonal change in the different regions LDX operates. Using Viradx and Febridx in Aus coming into the winter months would balance the trough they would see in US sales as example, however we may see that product sales reduce during spring/summer in US but services revenue pickup?

We need to see some other news outside of Hologic and the general product information we have had ie. Micropak, Aptatek, Food in Depth and seeing product and potential ongoing revenue identified from these existing deals.